Compare · LONA vs SRPT
LONA vs SRPT
Side-by-side comparison of LeonaBio Inc. (LONA) and Sarepta Therapeutics Inc. (SRPT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. LONA focuses on Biotechnology: Biological Products (No Diagnostic Substances), while SRPT focuses on Biotechnology: Pharmaceutical Preparations.
- SRPT is the larger of the two at $1.52B, about 47.2x LONA ($32.2M).
- SRPT has been more active in the news (8 items in the past 4 weeks vs 7 for LONA).
- SRPT has more recent analyst coverage (25 ratings vs 4 for LONA).
- Company
- LeonaBio Inc.
- Sarepta Therapeutics Inc.
- Price
- -
- -
- Market cap
- $32.2M
- $1.52B
- 1M return
- -46.42%
- -
- 1Y return
- -37.44%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 7
- 8
- Recent ratings
- 4
- 25
Sarepta Therapeutics Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Latest LONA
- LeonaBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update
- SEC Form SCHEDULE 13G filed by LeonaBio Inc.
- SEC Form SCHEDULE 13G filed by LeonaBio Inc.
- Large owner Portman David J. bought $9,919,161,281 worth of shares (3,149,470 units at $3,149.47) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by LeonaBio Inc.
- SEC Form 4 filed by LeonaBio Inc.
- LeonaBio Inc. filed SEC Form 8-K: Other Events
- SEC Form 3 filed by new insider Portman David J.
- LeonaBio to Participate in Cantor Global Healthcare Conference 2026
Latest SRPT
- SEC Form 13F-HR filed by Sarepta Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Sarepta Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Sarepta Therapeutics Inc.
- Sarepta Therapeutics upgraded by Deutsche Bank with a new price target
- Sarepta Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments
- SEC Form 10-Q filed by Sarepta Therapeutics Inc.
- Sarepta Therapeutics to Present at Upcoming Investor Conferences
- Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
- Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting